Form 4: Amgen Director Ellen Kullman Receives Stock Grant

Amgen Inc. director Ellen J. Kullman acquired 665 shares of common stock through the immediate vesting of restricted stock units.

Summary

• Director Ellen J. Kullman was granted 665 restricted stock units (RSUs) on May 19, 2026.
• The RSUs vested immediately under the Amgen Inc. 2009 Director Incentive Program.
• Following this transaction, the director's total beneficial ownership increased to 14,535.9807 shares of common stock.
• The shares were acquired at a price of $0 per share as part of director compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that has no material impact on the company's financial outlook.

Positives

• Director alignment with shareholder interests is maintained through equity-based compensation.
• The transaction reflects standard corporate governance practices for director remuneration.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of director compensation, which is standard practice among large-cap biotechnology firms to ensure board members maintain a financial stake in the company's performance.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices at major pharmaceutical companies like Pfizer, Merck, and Gilead Sciences.
• Immediate vesting of director equity is a common mechanism for board compensation in the S&P 500.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Amgen, AMGN, Form 4, Director Compensation, Insider Transaction, Equity Incentive Plan